Best Safest Stocks To Invest In 2019

Despite several years of steady declines, deadly vehicle crashes are on the rise, according to the most recent data from the National Highway Traffic Safety Administration.

The safest day to be on the road: Tuesday. The most dangerous? Saturday.

That’s according to a newstudy by Avvo, an online legal referral and review site, which analyzed data from NHTSA’s Fatality Analysis Reporting System in 2016 on how many car crash-related fatalities happened across the country by weekday and time of day.

The analysis found that 6,802 lives were lost on Saturday out of the 37,461 road deaths that occurred in 2016. That was 53% higher than the 4,444 deaths that happened on a Tuesday, the day with the least number of crash-related fatalities.

The second and third deadliest days were also associated with the weekend: Friday (5,826) and Sunday (5,809).

Best Safest Stocks To Invest In 2019: ImmuCell Corporation(ICCC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ImmuCell (NASDAQ:ICCC) released its quarterly earnings results on Monday. The biotechnology company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. ImmuCell had a negative net margin of 1.61% and a negative return on equity of 0.79%.

Best Safest Stocks To Invest In 2019: Smith & Nephew SNATS, Inc.(SNN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Zimmer Biomet (NYSE: ZBH) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

  • [By Stephan Byrd]

    Wells Fargo & Company MN lifted its holdings in Smith & Nephew plc (NYSE:SNN) by 1.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 390,356 shares of the medical equipment provider’s stock after purchasing an additional 5,951 shares during the quarter. Wells Fargo & Company MN owned 0.09% of Smith & Nephew worth $14,893,000 as of its most recent SEC filing.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Benzinga News Desk]

    Weight Watchers (NYSE: WTW) is tipping the scales on Wall Street: Link

    ECONOMIC DATA
    USA Nonfarm Payrolls for Apr 164.0K vs 189.0K Est; Prior 103.0K. Private Payrolls for Apr 168.0K vs 194.0K Est; Prior 102.0K
    Unemployment Rate for Apr 3.90% vs 4.00% Est; Prior 4.10%
    New York Fed President William Dudley is set to speak at 12:45 p.m. ET.
    The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.
    Federal Reserve Bank of San Francisco President John Williams will speak at 3:00 p.m. ET.
    Randal Quarles, Vice Chairman for Supervision, is set to speak at 5:30 p.m. ET.
    Dallas Fed President Robert Kaplan will speak at 8:00 p.m. ET.
    Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 8:00 p.m. ET.
    Kansas City Fed President Esther George will speak at 8:00 p.m. ET.
    ANALYST RATINGS
    RBC upgraded Benefitfocus (NASDAQ: BNFT) from Sector Perform to Outperform
    Stephens upgraded FMC (NYSE: FMC) from Equal-Weight to Overweight
    RBC downgraded Colfax (NYSE: CFX) from Outperform to Sector Perform
    Deutsche Bank downgraded Smith & Nephew (NYSE: SNN) from Hold to Sell

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

Best Safest Stocks To Invest In 2019: Cowen Group, Inc.(COWN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine cut shares of Cowen Inc Class A (NASDAQ:COWN) from a hold rating to a sell rating in a report published on Friday.

    COWN has been the subject of a number of other reports. BidaskClub upgraded shares of Cowen Inc Class A from a sell rating to a hold rating in a research note on Saturday, April 7th. Sandler O’Neill started coverage on shares of Cowen Inc Class A in a research note on Friday, May 18th. They issued a buy rating and a $19.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. Cowen Inc Class A presently has an average rating of Hold and an average price target of $17.67.

  • [By Ethan Ryder]

    Cowen Inc Class A (NASDAQ:COWN) Director Peter A. Cohen sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $15.19, for a total value of $37,975.00. Following the completion of the sale, the director now owns 698,095 shares in the company, valued at approximately $10,604,063.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

  • [By Joseph Griffin]

    MetLife Investment Advisors LLC bought a new stake in Cowen Group (NASDAQ:COWN) in the fourth quarter, HoldingsChannel.com reports. The fund bought 13,196 shares of the financial services provider’s stock, valued at approximately $180,000.

  • [By Joseph Griffin]

    Waddell & Reed (NYSE: WDR) and Cowen Group (NASDAQ:COWN) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

  • [By Sean Williams]

    According to a new note published this past week by investment firm Cowen (NASDAQ:COWN), the total cannabis market could generate as much as $75 billion in gross annual sales by 2030, up from a previous forecast of $50 billion by 2026.

  • [By Max Byerly]

    Thompson Siegel & Walmsley LLC reduced its stake in Cowen Group (NASDAQ:COWN) by 6.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 750,063 shares of the financial services provider’s stock after selling 50,848 shares during the period. Thompson Siegel & Walmsley LLC owned 2.54% of Cowen Group worth $9,900,000 at the end of the most recent quarter.

Best Safest Stocks To Invest In 2019: Alder BioPharmaceuticals, Inc.(ALDR)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Shares of Alder Biopharmaceuticals (NASDAQ:ALDR), a clinical-stage biotech focused on migraines, rose as much as 14% in afternoon trading on Friday. The jump was in response to the news that Teva Pharmaceutical Industries (NYSE:TEVA) is scrapping part of a late-stage study of a potential rival to Alder’s lead compound eptinezumab. Alder’s stock has since cooled off, but was still up about 6% as of 3:58 p.m. EDT.

  • [By Joseph Griffin]

    Mizuho reaffirmed their buy rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Thursday morning. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.

  • [By Cory Renauer]

    Migraines affect perhaps a billion people the world over, and it’s been three decades since they had a new preventative treatment option. That means there could be enough demand to driveblockbuster sales for a new class of treatments making their way to consumers right now, one of which could come fromlittle Alder Biopharmaceuticals Inc. (NASDAQ:ALDR).

  • [By Ethan Ryder]

    Needham & Company LLC assumed coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report issued on Wednesday. The brokerage issued a buy rating and a $28.00 price objective on the biopharmaceutical company’s stock.

  • [By Ethan Ryder]

    Alder Biopharmaceuticals (NASDAQ:ALDR) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday.

  • [By Stephan Byrd]

    BidaskClub cut shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from a strong-buy rating to a buy rating in a report released on Tuesday.

    A number of other equities research analysts have also weighed in on the company. Goldman Sachs Group initiated coverage on Alder Biopharmaceuticals in a research report on Tuesday, April 24th. They set a neutral rating and a $17.00 price objective on the stock. Mizuho restated a buy rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research report on Wednesday, March 28th. Cowen set a $23.00 price target on Alder Biopharmaceuticals and gave the company a buy rating in a research report on Monday, February 26th. Leerink Swann reiterated an outperform rating on shares of Alder Biopharmaceuticals in a research report on Sunday, March 4th. Finally, Zacks Investment Research lowered Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. Alder Biopharmaceuticals currently has an average rating of Buy and a consensus target price of $26.33.

Best Safest Stocks To Invest In 2019: EMCORE Corporation(EMKR)

Advisors’ Opinion:

  • [By Max Byerly]

    News stories about EMCORE (NASDAQ:EMKR) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EMCORE earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the semiconductor company an impact score of 45.6118508960632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is themostshorted stock on theNASDAQ with short interest of 62.65% according to Highshortnterest.com.

Leave a Reply

Your email address will not be published. Required fields are marked *